Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone714-508-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.62 million
Profitability
Miscellaneous
Employees186
Next Earnings Date3/11/2019 (Estimated)
OptionableOptionable
Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions
What is Avid Bioservices' stock symbol?
Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?
Avid Bioservices announced a dividend on Wednesday, March 7th. Stockholders of record on Monday, March 19th will be paid a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date of this dividend is Friday, March 16th. View Avid Bioservices' Dividend History.
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.
How were Avid Bioservices' earnings last quarter?
Avid Bioservices Inc (NASDAQ:CDMO) issued its quarterly earnings data on Monday, December, 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $10.18 million during the quarter, compared to analyst estimates of $10.75 million. Avid Bioservices had a negative net margin of 31.20% and a negative return on equity of 38.67%. View Avid Bioservices' Earnings History.
When is Avid Bioservices' next earnings date?
What guidance has Avid Bioservices issued on next quarter's earnings?
Avid Bioservices updated its FY 2019 earnings guidance on Monday, December, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $51-55 million, compared to the consensus revenue estimate of $54.3 million.
What price target have analysts set for CDMO?
4 brokers have issued 12-month target prices for Avid Bioservices' stock. Their predictions range from $4.00 to $11.00. On average, they anticipate Avid Bioservices' share price to reach $8.3333 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price. View Analyst Price Targets for Avid Bioservices.
What is the consensus analysts' recommendation for Avid Bioservices?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.
Has Avid Bioservices been receiving favorable news coverage?
Headlines about CDMO stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avid Bioservices earned a news sentiment score of 0.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Avid Bioservices' key competitors?
Some companies that are related to Avid Bioservices include Advanz Pharma (CXRXF), Homology Medicines (FIXX), Retrophin (RTRX), Athenex (ATNX), ImmunoGen (IMGN), Radius Health (RDUS), CytomX Therapeutics (CTMX), Apellis Pharmaceuticals (APLS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), Inflarx (IFRX), G1 Therapeutics (GTHX), Intra-Cellular Therapies (ITCI), ANI Pharmaceuticals (ANIP) and Omeros (OMER).
What other stocks do shareholders of Avid Bioservices own?
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the folowing people:
- Dr. Roger J. Lias, Pres, CEO & Director (Age 59)
- Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. Daniel R. Hart, Chief Financial Officer (Age 46)
- Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 44)
- Ms. Tracy L. Kinjerski, VP of Bus. Operations
Who are Avid Bioservices' major shareholders?
Avid Bioservices' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.39%), AltraVue Capital LLC (2.35%), Northern Trust Corp (1.07%), Sargent Investment Group LLC (0.99%), Geode Capital Management LLC (0.94%) and Bandera Partners LLC (0.71%). Company insiders that own Avid Bioservices stock include Joel Mccomb and Mark R Bamforth. View Institutional Ownership Trends for Avid Bioservices.
Which institutional investors are selling Avid Bioservices stock?
CDMO stock was sold by a variety of institutional investors in the last quarter, including Bandera Partners LLC, Stifel Financial Corp, Millennium Management LLC, Northern Trust Corp, Connor Clark & Lunn Investment Management Ltd. and MetLife Investment Advisors LLC. View Insider Buying and Selling for Avid Bioservices.
Which institutional investors are buying Avid Bioservices stock?
CDMO stock was bought by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Sargent Investment Group LLC, Legato Capital Management LLC, Geode Capital Management LLC, Rhumbline Advisers, Bank of America Corp DE, Jane Street Group LLC and Virtu Financial LLC. View Insider Buying and Selling for Avid Bioservices.
How do I buy shares of Avid Bioservices?
Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avid Bioservices' stock price today?
One share of CDMO stock can currently be purchased for approximately $4.09.
How big of a company is Avid Bioservices?
Avid Bioservices has a market capitalization of $229.33 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-21,810,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 186 workers across the globe.
What is Avid Bioservices' official website?
How can I contact Avid Bioservices?
Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]
MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
